Search clinical trials for: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Total 56 results

Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

COVID-19 | Influenza

China
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Covid19

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE... and other collaborators

Recruiting

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

COVID-19

China
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

COVID-19

China
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

COVID-19

China
Beijing Minhai Biotechnology Co., Ltd
Shenzhen Kangtai Biological Products Co., LTD; Jiangsu Province Centers for...

Unknown

A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

COVID-19

China
Beijing Minhai Biotechnology Co., Ltd
Shenzhen Kangtai Biological Products Co., LTD; Jiangsu Province Centers for...

Unknown

A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Active, not recruiting

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

COVID-19

China
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
Sinovac Research and Development Co., Ltd.

Recruiting

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

COVID-19

China
Pontificia Universidad Catolica de Chile

Completed

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

COVID-19 | SARS-CoV-2 Infection | Solid Organ Transplant | Vaccine Response Impaired

Chile
Binhui Biopharmaceutical Co., Ltd.

Recruiting

Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

COVID-19

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE...

Recruiting

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

COVID-19

China
Sinovac Biotech Co., Ltd

Active, not recruiting

Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19

COVID-19

China
Collegium Medicum w Bydgoszczy

Active, not recruiting

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study (DANTE-SIRIO 7)

SARS-CoV2 Infection | SARS-CoV2 Antibodies

Poland
Collegium Medicum w Bydgoszczy

Recruiting

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation (DANTE-SIRIO 8)

SARS-CoV2 Infection | SARS-CoV2 Antibodies

Poland
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.

Not yet recruiting

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

SARS-CoV-2
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

SARS-CoV-2

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Not yet recruiting

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People

SARS-CoV-2
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
CyanVac LLC

Completed

Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents (CVXGA1-001)

Covid19

United States
Poitiers University Hospital

Completed

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution (BIOMARK-COVID)

Covid19

France
Zhongnan Hospital

Recruiting

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

SARS-CoV-2 | Safety | Immunotoxicity

China
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
Korea University Guro Hospital
Korean Center for Disease Control and Prevention

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
University Hospital, Ghent

Completed

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (IPV-004)

Poliomyelitis

Belgium
IRCCS Sacro Cuore Don Calabria di Negrar

Recruiting

Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups. (COVaxFragile)

COVID-19

Italy
Vaxart

Active, not recruiting

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Norovirus Infections

United States
International Vaccine Institute
Heidelberg University; International Centre for Diarrhoeal Disease Research... and other collaborators

Active, not recruiting

Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines

Covid19

Madagascar, Mozambique
Gamaleya Research Institute of Epidemiology and...
Russian Direct Investment Fund

Active, not recruiting

An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine

COVID-19 Prevention

Russian Federation
Rambam Health Care Campus
Boehringer Ingelheim

Unknown

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients (ERA-HF)

Heart Failure | Diabetes Mellitus | Arrythmia
Novavax

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

COVID-19
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaborators

Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19 (Sisonke)

SARS (Severe Acute Respiratory Syndrome)

South Africa
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
Memorial Sloan Kettering Cancer Center
Pfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of Virginia

Completed

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Neurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial Hemangiopericytoma

United States
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Rambam Health Care Campus

Unknown

Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation

Inadequate Preparation for Colonoscopy; Personalized Colonoscopy Preparation

Israel
Ashutosh Kumar Tewari
Oncovir, Inc.

Recruiting

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Prostate Cancer Patients on Active Surveillance

United States
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

Influenza

Switzerland
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

EGFR-Mutant Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States

3

Subscribe